<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30194148</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>14</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1791-7530</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>38</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Anticancer research</Title>                <ISOAbbreviation>Anticancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>Effect of Vitamin D on Paclitaxel Efficacy in Triple-negative Breast Cancer Cell Lines.</ArticleTitle>            <Pagination>                <MedlinePgn>5043-5048</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.12823</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer that disproportionately affects women with darker skin and is often treated with paclitaxel (PTX). Here, the effect of vitamin D on p53-positive DU4475 cells and its ability to decrease the IC<sub>50</sub> of PTX in these cells were investigated.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The growth inhibitory effects of vitamin D on DU4475 cells and the effect of PTX plus vitamin D on overall TNBC cell viability was assessed using CellTiter-Glo®.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Vitamin D increased proliferation of DU4475 cells at low concentrations and lowered the IC<sub>50</sub> of PTX. However, it did not change the IC<sub>50</sub> of PTX in MDA-MB-231 cells which remained largely viable.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The effect of vitamin D on DU4475 cell viability was different than in other TNBC cells. The effect of PTX on DU4475 cells was enhanced with vitamin D. MDA-MB-231 cells were relatively resistant to the effects of PTX.</AbstractText>                <CopyrightInformation>Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Wilhelm</LastName>                    <ForeName>Catherine A</ForeName>                    <Initials>CA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, University of Michigan-Flint, Flint, MI, U.S.A.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Clor</LastName>                    <ForeName>Zackary J</ForeName>                    <Initials>ZJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, University of Michigan-Flint, Flint, MI, U.S.A.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kelts</LastName>                    <ForeName>Jessica L</ForeName>                    <Initials>JL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry and Biochemistry, University of Michigan-Flint, Flint, MI, U.S.A. jkelts@umflint.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Greece</Country>            <MedlineTA>Anticancer Res</MedlineTA>            <NlmUniqueID>8102988</NlmUniqueID>            <ISSNLinking>0250-7005</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D016159">Tumor Suppressor Protein p53</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>1406-16-2</RegistryNumber>                <NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P88XT4IS4D</RegistryNumber>                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016159" MajorTopicYN="N">Tumor Suppressor Protein p53</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">paclitaxel</Keyword>            <Keyword MajorTopicYN="N">triple-negative breast cancer</Keyword>            <Keyword MajorTopicYN="N">vitamin D</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>30</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30194148</ArticleId>            <ArticleId IdType="pii">38/9/5043</ArticleId>            <ArticleId IdType="doi">10.21873/anticanres.12823</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>